Trillium Therapeutics Inc (TRIL)

22.17
-0.09(-0.40%)
  • Volume:
    16,151
  • Bid/Ask:
    22.16/22.18
  • Day's Range:
    22.13 - 22.36
  • Type:Equity
  • Market:Canada
  • ISIN:CA89620X5064
  • CUSIP:89620X506

TRIL Overview

Prev. Close
22.26
Day's Range
22.13-22.36
Revenue
49.47K
Open
22.26
52 wk Range
7.48-27.12
EPS
-0.62
Volume
16,151
Market Cap
2.34B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
183,667
P/E Ratio
-
Beta
1.87
1-Year Change
36.73%
Shares Outstanding
104,995,125
Next Earnings Date
Nov 05, 2021
What is your sentiment on Trillium Therapeutics Inc?
or
Vote to see community's results!

Trillium Therapeutics Inc News

Trillium Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellSellStrong BuyStrong Buy

Trillium Therapeutics Inc Company Profile

Trillium Therapeutics Inc Company Profile

Employees
0
Market
Canada

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Read More
  • Keep an eye on Celsion Corp (CLSN). It will explode +400%!!!
    0
    • Why dod you say that? I just need to know as i invest here.
      0
    • *did.Thank you.
      0
  • Lucky SOB’s
    0
    • Lucky f uk s
      0
      • what's going on here, falling like a rain.
        0
        • faling,rocket time !
          0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.